FDA Clearance Tracker · P250003-S008
Embrace(TM) Hydrogel Embolic System
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Oct 23, 2026
Approved
Time to decision
178 days
Received Apr 28, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P250003-S008
- Device name
- Embrace(TM) Hydrogel Embolic System
- Applicant
- Instylla, Inc.
- Applicant location
- Bedford, MA
- Received
- Apr 28, 2026
- Decided
- Oct 23, 2026
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P250003
Device type
- Device type
- Embolization Agent, Vascular (QVG)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
This device is indicated for embolization of hypervascular tumors in peripheral arteries = 5mm and peripheral arterial bleeds in vessels = 6mm.
Source documents
Other decisions for Instylla, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Verge Microcatheter510(k)
K261610 · Decided Jun 11, 2026 · 28 days after receipt
Device type: Catheter, Continuous Flush (KRA) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.